CORRESP Filing
ACTUATE THERAPEUTICS, INC.
Date: July 31, 2025 · CIK: 0001652935 · Accession: 0001683168-25-005548
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288952
Letter
Actuate Therapeutics, Inc. 1751 River Run, Suite 400
Fort Worth, TX 76107
July 31, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tyler Howes
Re: Actuate Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-288952
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Actuate Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to August 4, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified of such effectiveness by a telephone call to Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564 and that such effectiveness also be confirmed in writing.
Very truly yours,
Actuate Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Actuate Therapeutics, Inc. 1751 River Run, Suite 400 Fort Worth, TX 76107 July 31, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: Actuate Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-288952 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Actuate Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to August 4, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. We request that we be notified of such effectiveness by a telephone call to Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564 and that such effectiveness also be confirmed in writing. Very truly yours, Actuate Therapeutics, Inc. By: /s/ Daniel M. Schmitt Daniel M. Schmitt President and Chief Executive Officer